Technology plays an essential role in how pharmaceutical firms conduct business in today’s digitally influenced world.
Continue readingCategory: Pharma
Pharmacy cyberattacks: Lessons for practitioners
A recent run of high-profile cyberattacks has highlighted the need for healthcare organisations to invest in continuing security initiatives.
Continue readingMedication mistakes are widespread for children with Leukaemia and Lymphoma, research revealed
According to research published in Cancer, medication mistakes are widespread in children with leukaemia or lymphoma, and these errors can
Continue readingUK Chemicals and Pharmaceuticals Industry Joins Forces for Flue2Chem Program to Transform Consumer Product Sustainability
Fifteen key players from the UK’s £73 billion chemicals and pharmaceuticals sector have signed an agreement to launch Flue2Chem, a
Continue readingFDA Approves Expansion of Pfizer’s Ibrance Label for Breast Cancer Treatment
Pfizer has announced a label expansion for its breast cancer drug, Ibrance, after the FDA extended its approval.
Continue readingFDA regulation requires barcodes on pharmaceutical packages
The FDA has approved a new regulation requiring pharmaceutical producers to include a bar code on all immediate-release medicine packages.
Continue readingXRP Healthcare launches the first decentralised pharmaceutical marketplace on XRP Ledger
XRP Healthcare is developing a decentralised pharmaceutical marketplace that will operate independently of central banking institutions.
Continue readingBayer anticipates Billion-Dollar sales potential from new blood thinning drug
Bayer anticipated that their experimental blood clot drug might generate more than 5 billion euros ($5.4 billion) in peak annual
Continue readingUnicycive’s crucial kidney medication trial achieves its primary objective
By publishing key bioequivalence results on a prospect created to increase adherence to treatment regimens for kidney illness, Unicycive Therapeutics
Continue readingUCB’s drug gets attention for hidradenitis suppurativa
The FDA rejected UCB’s much awaited psoriasis treatment bimekizumab as a result of problems with facility inspections, therefore the firm
Continue reading
English